62.24
2.94%
+1.78
Lantheus Holdings Inc stock is currently priced at $62.24, with a 24-hour trading volume of 1.03M.
It has seen a +2.94% increased in the last 24 hours and a -4.79% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $60.13 pivot point. If it approaches the $62.03 resistance level, significant changes may occur.
Lantheus Holdings Inc Stock (LNTH) Financials Data
Lantheus Holdings Inc (LNTH) Revenue 2023
LNTH reported a revenue (TTM) of $1.30 billion for the quarter ending December 31, 2023, a +38.65% rise year-over-year.
Lantheus Holdings Inc (LNTH) Net Income 2023
LNTH net income (TTM) was $326.66 million for the quarter ending December 31, 2023, a +1,064% increase year-over-year.
Lantheus Holdings Inc (LNTH) Cash Flow 2023
LNTH recorded a free cash flow (TTM) of $258.70 million for the quarter ending December 31, 2023, a -1.80% decrease year-over-year.
Lantheus Holdings Inc (LNTH) Earnings per Share 2023
LNTH earnings per share (TTM) was $4.64 for the quarter ending December 31, 2023, a +1,265% growth year-over-year.
Lantheus Holdings Inc Stock (LNTH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Sabens Andrea | Chief Accounting Officer |
Mar 13 '24 |
Sale |
60.48 |
341 |
20,624 |
63,204 |
Blanchfield Paul | President |
Mar 07 '24 |
Sale |
61.96 |
18,023 |
1,116,705 |
103,357 |
LENO SAM R | Director |
Mar 06 '24 |
Option Exercise |
16.30 |
2,045 |
33,334 |
59,982 |
Lantheus Alpha Therapy, LLC | 10% Owner |
Mar 06 '24 |
Buy |
0.95 |
60,431,039 |
57,409,487 |
116,773,394 |
LENO SAM R | Director |
Mar 06 '24 |
Sale |
63.50 |
2,045 |
129,857 |
57,937 |
LENO SAM R | Director |
Mar 05 '24 |
Option Exercise |
16.30 |
2,045 |
33,334 |
59,982 |
LENO SAM R | Director |
Mar 05 '24 |
Sale |
64.62 |
2,045 |
132,148 |
57,937 |
LENO SAM R | Director |
Mar 04 '24 |
Option Exercise |
19.85 |
22,389 |
444,499 |
80,326 |
Heino Mary Anne | Director |
Mar 04 '24 |
Sale |
65.31 |
93,863 |
6,129,889 |
251,643 |
LENO SAM R | Director |
Mar 04 '24 |
Sale |
65.42 |
22,389 |
1,464,749 |
57,937 |
Lantheus Holdings Inc Stock (LNTH) Latest News
Acadia (ACHC) Starts Construction of Malden's JV Facility
Zacks Investment Research
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
Zacks Investment Research
Lantheus Holdings (LNTH) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks Investment Research
Is Most-Watched Stock Lantheus Holdings, Inc. (LNTH) Worth Betting on Now?
Zacks Investment Research
Lantheus (LNTH) Is Considered a Good Investment by Brokers: Is That True?
Zacks Investment Research
Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?
Zacks Investment Research
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Cap:
|
Volume (24h):